Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex.
Growing evidence indicates that there is an interaction between the transmission of dopamine (DA) and norepinephrine (NE) in the noradrenergic and dopaminergic projections that converge in the medial prefrontal cortex (mPFC). The effects of the noradrenergic alpha1 and alpha2 receptors and the NE transporters on the DA outflow and those of the dopaminergic D1 and D2 receptors on NE release in the mPFC were investigated. Local infusions of NE (90, 150, and 300 nM) into the mPFC increased the extracellular release of DA in anesthetized rats. The alpha1 receptor antagonist (10 microM prazosin), but not the alpha2 receptor antagonist (100 microM piperoxan), blocked the NE-induced increase of DA in the mPFC. In addition, local infusion of alpha1 receptor agonist (10 microM phenylephrine) enhanced DA release in the mPFC. Local application of DA in different concentrations into the mPFC increased extracellular NE levels. Intra-mPFC infusion of a D1 receptor antagonist (10 nM SCH23390), inhibited the DA-induced increase of NE; this did not happen with a D2 receptor antagonist (1 nM eticlopride). Local administration of a selective NE uptake inhibitor (1 microM desmethylimipramine) into the mPFC increased the outflows of both DA and NE in the mPFC. However, co-infusion of DMI and prazosin blunted, but did not totally abolish, the DMI-increase in the extracellular levels of DA and NE. These results suggest that in the mPFC, 1) extracellular NE could enhance DA release by activating the alpha1 receptors; and 2) extracellular DA increased the extracellular levels of NE by activating the D1 receptors.
Pan
Wynn H T
WH
Institute of Pharmacology, School of Life Sciences, National Yang-Ming University, Taipei, Taiwan, R.O.C.
Yang
Sze-Yuan
SY
Lin
Shi-Kwang
SK
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage; D000818:Animals; D004298:Dopamine / Q000008:administration & dosage / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000008:administration & dosage; D007276:Injections, Intraventricular; D008297:Male; D017551:Microdialysis; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009638:Norepinephrine / Q000008:administration & dosage / Q000378:metabolism*; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D017447:Receptors, Dopamine D1 / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D018492:Dopamine Antagonists; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D004298:Dopamine; D009638:Norepinephrine